Online inquiry

IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5790MR)

This product GTTS-WQ5790MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ5790MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3355MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ5211MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ14161MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ11196MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ2766MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ4574MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ9517MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ15706MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VEGF Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW